98%
921
2 minutes
20
Background: This systematic review aims to identify the benefits and harms of electronic cigarettes (e-cigarettes) as a smoking cessation aid in adults (aged ≥ 18 years) and to inform the development of the Canadian Task Force on Preventive Health Care's (CTFPHC) clinical practice guidelines on e-cigarettes.
Methods: We searched Ovid MEDLINE®, Ovid MEDLINE® Epub Ahead of Print, In-Process & Other Non-Indexed Citations, PsycINFO, Embase Classic + Embase, and the Cochrane Library on Wiley. Searches were conducted from January 2016 to July 2019 and updated on 24 September 2020 and 25 January 2024. Two reviewers independently performed title-abstract and full-text screening according to the pre-determined inclusion criteria. Data extraction, quality assessments, and the application of Grading of Recommendations Assessment, Development and Evaluation (GRADE) were performed by one independent reviewer and verified by another.
Results: We identified 18 studies on 17 randomized controlled trials that compared e-cigarettes with nicotine to e-cigarettes without nicotine and e-cigarettes (with or without nicotine) to other interventions (i.e., no intervention, waitlist, standard/usual care, quit advice, or behavioral support). Considering the benefits of e-cigarettes in terms of smoking abstinence and smoking frequency reduction, 14 studies showed small or moderate benefits of e-cigarettes with or without nicotine compared to other interventions; although, with low, very low or moderate evidence certainty. With a focus on e-cigarettes with nicotine specifically, 12 studies showed benefits in terms of smoking abstinence when compared with usual care or non-nicotine e-cigarettes. In terms of harms following nicotine or non-nicotine e-cigarette use, 15 studies reported mild adverse events with little to no difference between groups and low to very low evidence certainty.
Conclusion: The evidence synthesis on the e-cigarette's effectiveness shows data surrounding benefits having low to moderate evidence certainty for some comparisons and very low certainty for others, indicating that e-cigarettes may or probably increase smoking cessation, whereas, for harms, there is low to very low evidence certainty. Since the duration for outcome measurement varied among different studies, it may not be long-term enough for Adverse Events (AEs) to emerge, and there is a need for more research to understand the long-term benefits and potential harms of e-cigarettes.
Systematic Review Registration: PROSPERO CRD42018099692.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11218295 | PMC |
http://dx.doi.org/10.1186/s13643-024-02572-7 | DOI Listing |
Nicotine Tob Res
September 2025
National Institute on Drug Abuse, 6001 Executive Blvd, N. Bethesda, Maryland 20852.
Introduction: Flavors play an important role in e-cigarette use among both young people and adults, but evaluations of flavored e-cigarette policies have focused almost exclusively on youth. This longitudinal study examined how flavored e-cigarette policies affect tobacco use over time for different adult age groups using data from the Population Assessment of Tobacco and Health (PATH) Study.
Methods: Adults age 21+ at Wave 5 (2018-2019) comprised the analytic sample.
JDR Clin Trans Res
September 2025
University of California San Francisco, School of Dentistry, San Francisco, CA, USA.
Objectives: This investigation aimed to examine the associations between xerostomia and the use of cigarettes, e-cigarettes, and cannabis in a nationally representative cross-sectional sample of adults.
Methods: Data from the Population Assessment of Tobacco and Health Study included = 29,721 United States adults (age ≥18 y) surveyed during 2022 to 2023 about xerostomia (experiencing dry mouth "frequently" or "always") and their use of 9 types of tobacco products and cannabis. Survey-weighted multivariable regression models estimated the associations of xerostomia with various specifications of cigarette, e-cigarette, and cannabis use, adjusted for sociodemographic and health status variables.
Chem Res Toxicol
September 2025
R&D Department, IMiracle (Shenzhen) Innovation Technology Co., Ltd., Junction of Menghai Boulevard and Binhai Avenue in Qianhai Shenzhen Hong Kong Cooperation Zone, Shenzhen 518100, China.
Nicotine lactate salt is one of the commonly used nicotine salts in electronic cigarette (e-cigarette) formulations, including products that have received Marketing Granted Orders through the FDA's Premarket Tobacco Product Application (PMTA) evaluation in the US. However, full-life cycle evaluation on nicotine lactate salt remains limited, especially its leaching reactions with heating elements and the potential to influence aerosol composition. This study investigated the chemical effects of nicotine lactate salt on e-cigarette heating coils and potential toxicological consequences of nickel (Ni) leachates using in vitro cells and animal models.
View Article and Find Full Text PDFPrev Med Rep
June 2025
Center for Tobacco Research, The Ohio State University Comprehensive Cancer Center, USA.
Objective: Nicotine concentration, form (salt vs. freebase), and type (synthetic vs. tobacco-derived) are key characteristics of e-cigarettes that manufacturers manipulate.
View Article and Find Full Text PDFBMJ Glob Health
September 2025
Department of Oral Medicine and Periodontology, University of Peradeniya, Peradeniya, Sri Lanka.
Introduction: E-cigarette use has become a significant global public health concern. Recently, several systematic reviews have synthesised evidence on e-cigarette use in Europe, America and Southeast Asia. However, there is no known systematic review of such on South Asia (SA).
View Article and Find Full Text PDF